Issue No: PHR-20260323-01

# OZEMPIC **PATENT EXPIRY**

A Quantitative Analysis Of The 2026 **Semaglutide Patent Cliff** And Its Multi-Sector Global Implication

IFSA Ramjas

# TABLE OF CONTENTS


**The Decoupling of Metabolic Economics** 01
A Quantitative Analysis of the 2026 Semaglutide Patent Cliff & Multi-Sector Global Implications- as of March14,2026.

**The Rise Of The Generics: Strategic Positioning Of The "Pharmacy Of The World** 03
50+ Generic Brands Launching In India. Price Expected To Drop From Rs 12, 000 To Rs 3500

**Innovator Crisis: The Erosion Of Novo Nordisk's Dominance** 05
Cagrisema Lost To Eli Lilly's Zepbound In Trials. Share Price Fell 46% From Its Peak.

**Microeconomic Shifts: The "Ozempic Effect" On Global Consumer Behavior** 07
GLP-1 Users Buy 6–10% Less Groceries. Fast Food Visits Down 77%, Alcohol Down 50%.

**Upstream Economics: Api Supply Chains And Manufacturing Arbitrage** 08
Ozempic costing ~$900/month, actual production costs are as low as $28–$140/year, giving Chinese and Indian generic makers massive profit margins.

**Geopolitics And Macro-fiscal Implications: The Ira And Global Trade** 09
Us Medicare Negotiations Will Save $12b/Year On Ozempic From 2027 Onwards.

**The Medical Device Halo Effect: Continuous Monitoring And CGMS** 10
Dexcom And Abbott Growing Alongside Glp-1 Adoption. Dexcom Revenue Up 16% In 2025.

**Structural Risks: Safety Warnings And Regulatory Hurdles** 11
FDA Safety Warnings Issued. Generic Price War And Batch Inconsistency Risks May Eliminate Smaller Manufacturers.

**Conclusion: Actionable Insights For The 2026-2030 Cycle** 12
Winners Will Be Low-cost Api Makers In China And Device Integrators In India Not The Molecule's Discoverers.

# THE GREAT DECOUPLING OF METABOLIC ECONOMICS

A Quantitative Analysis of the 2026 Semaglutide Patent Cliff & Multi-Sector Global Implications- as of March, 2026.

# $250B

Total addressable market in obesity & diabetes therapeutics currently at the inflection point of its most significant structural shift in history.

## Market Divergence

**Protected vs. Liberalized Markets**

GLP-1 valuations are tied to uneven IP protections. **US, EU, and Japan** remain insulated until the early 2030s, while **China, India, Brazil, and Canada** have entered a commodity cycle creating a massive global pricing divergence.

## China Ruling

**Supreme People's Court — CN101133082B**

China's Supreme Court upheld the semaglutide compound patent until **March 20, 2026**, reversing earlier invalidation attempts. Post-filing data on **"surprising pharmacokinetic effects"** secured Novo Nordisk a final exclusivity window before the hard stop.

## INDIA & G7 ENTRY

**Delhi High Court Opens Export Channels**

India's composition patent lapsed in late 2024. The **Delhi High Court rejected** Novo Nordisk's attempts to block semaglutide manufacture for export turning India into a global generics launchpad ahead of its own domestic cliff.

## CANADA — FIRST G7 LOSS

**Data Protection Expires January 2026**

Canada became the first G7 market to see loss of exclusivity, with immediate filings from **Sandoz, Apotex, and Teva** setting the template for generic entry dynamics in developed markets ahead of US and EU timelines.

---

**Mar 20, 2026**
Patent Cliff

**2030s**
US/EU Exclusivity End

**3+**
**G7** Generic Entrants

# GLOBAL PATENT LANDSCAPE



## Global Patent Protection

The United States and European Union maintain active patent protection, shielding against generic competition. China, India, and Brazil are in the expiring phase, while Canada's patent has already expired. Russia holds a compromised status due to compulsory licensing provisions.

## Expiration Timeline

Canada's patent expired in January 2026, making it the first major market to open. China, India, and Brazil follow in March 2026. The European Union extends to March 2031, the United States to December 2031, while Russia remains a legally contested active case.

## Market Impact by Region

The United States and European Union keep generics at bay into the 2030s. China and India face fierce price wars with 50+ brands launching. Canada faces pricing pressure, Brazil confronts local competition after a denied extension, and Russia enables domestic production under compulsory licenses.

# RISE OF THE GENERICS

## Strategic Positioning of the "Pharmacy of the World"

### Strategic positioning in Semaglutide

The expiry of semaglutide patents has triggered a rapid shift in the Indian pharmaceutical market. What was once a supply-constrained innovator market is now moving toward broad generic participation, with more than 50 brands expected to enter. Many companies are adopting the “Sema” prefix to preserve prescriber familiarity and accelerate market acceptance.




**Price Reset**

Monthly therapy cost is expected to decline from the innovator range of Rs 10, 000–12, 000 to an initial generic range of Rs 3, 500–4, 000.

**RS 500-800**

As the price war matures, costs could drop as low as Rs 500–800 per month, making semaglutide significantly more affordable than current innovator pricing.

**Access Expansion**

As competition matures, some analysts estimate prices could fall further to Rs 500–800 per month, supporting wider access across diabetes and obesity care.

**135M+**

At this price point, the molecule could effectively democratize access for India's 100 million Type-2 diabetics and 135 million overweight individuals.

# Strategic Positioning of the "Pharmacy of the World"

**Dr. Reddy's** :Dr. Reddy's launches Obeda and Diagluton at 60% below innovator pricing

**Alkem Laboratories :** Alkem deploys Semaglide and Obesema aggressively across T2DM

**Sun Pharma** : Sun Pharma enters Day 1 with Noveltreat and Sematrinity

**Torrent Pharma :** Torrent launches Semastar and Semalix with oral and injectable approvals and SEC nod

**Zydus Lifesciences :** Zydus launches Semaglyn with a reusable multi-dose pen on Day 1.

**MSN Laboratories :** MSN's Semabig targets through injection vials backed by large-scale API supply

The patent expiry on semaglutide has triggered a generic gold rush in India, with 50+ brands launching simultaneously and monthly therapy costs expected to fall from Rs 10, 000–12, 000 to as low as Rs 500–800 , potentially democratizing access for India's 100 million Type-2 diabetics and 135 million overweight individuals.

Key players include Dr. Reddy's (Obeda, Diagluton), Sun Pharma (Noveltreat, Sematrinity), Zydus (Semaglyn, Mashema), Alkem (Semaglide, Obesema), Torrent (Semastar, Semalix), and MSN Laboratories (Semabig) , each differentiating on price, device design, channel strategy, or formulation breadth.

The competitive battleground has shifted from prescription acquisition to retention gaming, with long-term supply consistency and digital patient support emerging as key differentiators. Zydus's reusable 15 mg multi-dose pen is a notable device-level differentiator against the disposable FlexTouch model favored by innovators.

# INNOVATOR CRISIS

The Erosion of Novo Nordisk's Dominance

For Novo Nordisk, 2026 marks a period of exceptional strategic vulnerability. Despite the success of Ozempic and Wegovy, which made the company Europe's most valuable firm, Novo Nordisk has repeatedly reduced its profit and sales outlook as it loses ground to Eli Lilly's tirzepatide. The company is now confronting a dual challenge: regional patent erosion and the weakening credibility of its next-generation obesity pipeline.

This pressure intensified in February 2026, when Phase III REDEFINE 4 data delivered a major setback to Novo Nordisk's long-term strategy. CagriSema, positioned as a next-generation combination therapy, failed to meet its primary endpoint against Eli Lilly's Zepbound. While the drug achieved 23% weight loss over 84 weeks, it remained below tirzepatide's 25.5%, exposing a meaningful efficacy gap and raising doubts about Novo Nordisk's ability to defend leadership through pipeline innovation.


**23%**

**CagriSema Efficacy**

Achieved over 84 weeks in Phase III

---

**25.5%**

**Tizerpatide Efficacy**

Setting a higher benchmark for obesity treatment

---

**15 – 16.5%**

**Market Reaction**

Triggered by disappointing REDEFINE 4 outcomes

---

**-8.5%**

**Fair Value Revision**

Reflecting reduced confidence in future upside

---

**- 41.2%**

**2035 Sales Reduction**

Lowered after weaker long-term commercial expectations

---

**~46%**

**LTM Share Price Fall**

Reflecting sustained investor concern over execution

The REDEFINE 4 outcome led to sharp valuation revisions. Novo Nordisk's fair value estimate declined from $59.00 / DKK 372 to $54.00 / DKK 343, while projected 2035 sales for CagriSema were reduced from DKK 85 billion to DKK 50 billion. At the same time, the company's position as Europe's most valuable firm came under pressure, with rivals such as LVMH and ASML gaining relative ground.

In response, Novo Nordisk shifted toward a high-dose strategy aimed at restoring competitiveness. This includes the development of a 7.2 mg semaglutide dose, three times the current standard, as well as the advancement of REDEFINE 11, expected in the first half of 2027, to assess the full weight-loss potential of CagriSema under optimized titration protocols.




However, market sentiment remains cautious. Brokerages have largely maintained "Hold" ratings, reflecting uncertainty over whether these measures will be sufficient to close the competitive gap. This caution is further reinforced by ongoing generic pressure in Asia and continued pricing headwinds in the U.S., both of which add to Novo Nordisk's widening strategic challenge.

Novo Nordisk's share price also reflected the scale of investor concern, falling from approximately $87.52 in January 2025 to around $47.42 by February 2026. The decline signaled weakening confidence not only in a single asset, but in the company's broader ability to sustain category leadership.

## STRATEGIC IMPLICATIONS

**Competitive gap is now visible**

Eli Lilly has established stronger performance benchmarks in obesity treatment.

**CagriSema failed to reset momentum**

The combination therapy did not demonstrate the superiority needed to restore confidence.

**Investor confidence has weakened**

The sharp market reaction reflected concern over Novo's long-term pipeline credibility.

**Future growth depends on pipeline renewal**

Novo Nordisk must prove it can regain differentiation in an increasingly crowded market.

IFSA
Ramjas

# THE "OZEMPIC EFFECT" ON GLOBAL CONSUMER BEHAVIOR

As the patent cliff lowers the price barrier, the number of users is projected to surge to 24 million in the US alone by 2035. This is causing a seismic shift in appetite that is reshaping multi-billion-dollar industries.

Early 2026 retail data shows that GLP-1 users are significantly altering shopping behavior. Households with a GLP-1 user spend 6–10% less on groceries than non-users, with the steepest declines in ultra-processed categories, snack spending is down 10%, and 25% of users have stopped consuming soda entirely.


**77% frequent less often**

Conagra/Tyson resizing portions to "smaller format"

**Fast Food**

**14.5% less in consumption**

NIQ reports 1, 158% surge in non-alcoholic wine sales.

**Alcohol**

**54% specifically seek labels**

Danone marketing high-protein yogurt to prevent muscle loss.

**High-Protein**

**10% increase in sales**

Retailers prioritizing "perimeter of store" over aisles.

**Fresh Produce**

**44% decrease in purchases**

Nestlé launching "Vital Pursuit" brand for GLP-1 users.

**Sugary Snacks**

A biological effect is driving this shift, about 50% of users report a “metallic taste” that curbs cravings for salty snacks. GLP-1 drugs act as a natural nudge, reducing demand and shifting preferences toward nutrient-dense foods, posing a long-term challenge for companies like General Mills.

# UPSTREAM **ECONOMICS**








China has established a leading position in the upstream peptide market, supported by advanced manufacturing capabilities, structural cost advantages, and early large-scale investments. Process optimization and economies of scale have significantly reduced peptide API production costs, enabling high efficiency and competitive pricing while reinforcing China's role in the global pharmaceutical supply chain. Leading players such as Sinopep-Allsino, Chengdu Shengnuo, and Hua Medicine leverage specialized, large-capacity facilities to enhance supply reliability and pricing power, positioning them to efficiently meet rising global demand for peptide-based therapeutics.

These facilities increasingly rely on biosynthetic fermentation processes, which are more cost-effective and scalable than traditional recombinant DNA methods used by incumbents like Novo Nordisk. Fermentation enables continuous, high-volume production with lower input costs and greater efficiency, making it ideal for large-scale peptide API manufacturing. In contrast, recombinant DNA techniques are more resource-intensive and less flexible to scale. This shift toward fermentation gives newer manufacturers a strong cost advantage, allowing them to compete more effectively and capture a larger share of the global supply chain.



# GEOPOLITICAL AND MACRO-FISCAL IMPLICATIONS

IFSA Ramjas

API Supply Chains and Manufacturing Arbitrage

01

## Round 1 (2026)

Implementation for 10 initial drugs. Estimated to generate $6 billion in annual program savings and reduce beneficiary out-of-pocket costs by an average of 44-50% ($1.5 billion).

02

## Round 2 (2027)

Implementation for selected drugs, including Ozempic. Projected to yield $12 billion in estimated annual program savings and $685 million in beneficiary savings

03

## Round 3 (2028)

Implementation for selected drugs, including Wegovy. Negotiations will take place in 2026, with exact program and beneficiary savings to be determined.

### Macroeconomic Impact

Goldman Sachs estimates that health gains from GLP-1 adoption among 15 million US workers could increase US GDP by 1% by 2028 due to improved productivity and reduced sick leave.

### Skinny Labels

A geopolitical friction point where generic companies in the EU and Asia gain approval strictly for non-patented indications (e.g., T2DM) to bypass active obesity patents.

### Macroeconomic Impact

Russia's use of compulsory licensing, seen in drugs like Quincenta and Semavik, allows it to bypass patents held by Novo Nordisk and produce cheaper domestic versions of semaglutide. This helps address rising diabetes and obesity cases while reducing dependence on expensive imported medicines.
This move is being closely watched by other developing countries with high disease burdens and tight healthcare budgets. If replicated, it could weaken global patent protections, increase access to affordable drugs, and challenge the pricing power of major pharmaceutical companies.

# THE MEDICAL DEVICE HALO EFFECT CONTINUOUS MONITORING AND CGMS




US Market Share




## GLP-1 CGM Synergy

One of the most surprising insights for the financial markets has been the "symbiotic" relationship between GLP-1s and Continuous Glucose Monitors (CGMs). Contrary to early fears that appetite suppression would reduce the need for glucose monitoring, data from Abbott (FreeStyle Libre) and Dexcom shows that CGM adoption has actually grown among GLP-1 users.




## Adherence-Driven Growth Dynamics

Analysis reveals that patients on GLP-1s have higher "sensor adherence", wearing the devices for more days per month, as they use the real-time data to validate their new dietary behaviors. Dexcom's 2025 revenue reached $4.66 billion, a 16% rise, driven in part by this "GLP-1 war" synergy. While Dexcom's 2026 outlook slightly lagged analyst expectations at $5.16–5.25 billion, the company remains a "quiet winner" as it focuses on international market share where generic semaglutide will expand the total addressable patient population.

# STRUCTURAL RISKS

## SAFETY WARNINGS AND REGULATORY HURDLES

### SAFETY WARNING

In March 2026, the FDA issued a warning letter to Novo Nordisk for failing to adequately report serious adverse events associated with semaglutide, including cases of suicidal ideation and one confirmed suicide among users. This represents a significant pharmacovigilance failure at the innovator level , one that carries heightened implications as the molecule transitions to a broader, less controlled market environment.

As semaglutide moves from the tightly controlled innovator supply chain to dozens of generic manufacturers across India and China, the risk of unreported side effects increases materially. The diffusion of manufacturing responsibility makes consistent adverse event tracking structurally more difficult, raising patient safety concerns that regulators have yet to fully address.

### REGULATORY HURDLES

The FDA's warning letter underscores that even the originator with its established pharmacovigilance infrastructure, struggled to meet mandatory reporting standards. For generic entrants operating under comparatively thinner compliance frameworks, this sets a troubling precedent for regulatory adherence across the broader semaglutide market.




### FORENSIC BEAR CASE

The "forensic bear case" for the generic gold rush centers on the structural risk that an unremitting price war will erode profitability faster than volume can grow. The competitive dynamics of a rapidly commoditizing molecule, absent meaningful differentiation, create conditions where margin compression becomes self-reinforcing.

With 50+ brands launching simultaneously in India, the market risks severe fragmentation, driving a race to the bottom in pricing. Under this scenario, only firms with the most efficient API production capabilities, namely Huadong and Dr. Reddy's, are positioned to survive, leaving the majority of new entrants commercially unviable.

# CONCLUSION
# ACTIONABLE INSIGHTS

STRATEGIC FRAMEWORK · 2026 –2030 METABOLIC ECONOMY CYCLE

## Supply Chain Arbitrage 01

Profit in the generic era flows to **"Upstream" API manufacturers in China** and **Device Integrators in India**. The capacity to produce semaglutide at $28/year while retailing at $40/month creates a sustainable, **high-volume profit pool** with structural barriers to compression.

## Sector Rotation The Ozempic Effect 02

The "Ozempic Effect" is deflationary for traditional CPG and food companies **Nestlé, PepsiCo, McDonald's** while simultaneously inflationary for **MedTech (Dexcom, Abbott)** and high-protein agricultural sectors. Portfolio rotation is non-negotiable.

## Innovator Pivot Novo vs. Lilly 03

**Novo Nordisk** must execute its **High-Dose and CagriSema Optimization** strategy (REDEFINE 11) by 2027 or risk commoditisation as a legacy insulin company. **Eli Lilly** currently holds the competitive edge in efficacy the primary driver of high-end US market share retention.

## Macro-Fiscal Gains for National Systems 04

Healthcare systems **Canada, NHS (UK)** will achieve significant budgetary relief as procurement shifts from branded Wegovy to **$40/month generics**. This surplus potentially unlocks broader public coverage for obesity treatments across previously excluded demographics.

*The liberalisation of semaglutide in* **March 2026** *will be remembered as the moment when metabolic health transitioned from a* **luxury available to the affluent G7 population** *to a* **global standard of care**, *a structural shift with decade-long investment consequences.*

# RESEARCH DESK

## Executives

### Anshpreet Singh

Patent expiry marks a structural shift from scarcity-driven pricing to volume-driven competition in GLP-1 markets.

### Viren Kakkar

Novo’s lifecycle strategy reflects a deliberate segmentation of innovation versus commoditization.

## Analysts

### Udit Yadav

Margin compression in legacy semaglutide will be offset through premiumization of next-gen therapies.

### Bhuvika Gupta

The post-expiry landscape favors scale players with manufacturing and distribution advantages.

### Yashraj Chandela

Pricing power will increasingly migrate from molecules to delivery formats and combinations.

### Ritesh Ruwali

Expanded affordability post-expiry could redefine obesity treatment from niche to mass-market therapy.

### Priyansh Bansal

Competitive dynamics will shift from clinical efficacy to cost efficiency and access.

IFSA Ramjas

The ultimate shift is from a drug-led model to a chronic care ecosystem play, were long-term patient lifetime value, not unit pricing, defines market leadership.

# BIBLIOGRAPHY

Abbott. (n.d.). Findings from our FreeStyle Libre/GLP-1 analysis. *Abbott Newsroom*. https://www.abbott.com/en-us/corpnewsroom/strategy-and-strength/findings-from-our-freestyle-libre-glp-1-analysis

AARP. (n.d.). 3 big Medicare prescription drug changes coming in 2026. *AARP*. https://www.aarp.org/medicare/future-medicare-drug-payment-changes-2026/

Apicule. (n.d.). Semaglutide API suppliers – manufacturers and distributors. *Apicule*. https://apicule.com/apis/semaglutide-suppliers/

Briggs, J., & Kodnani, D. (2024, March 7). Obesity drugs are among health breakthroughs forecast to boost GDP. *Goldman Sachs*. https://www.goldmansachs.com/insights/articles/obesity-drugs-are-among-breakthroughs-forecast-GDP

Ching & Cheng Law. (n.d.). The Supreme Court made a favorable ruling on the patent of semaglutide compound. *Ching & Cheng Law*. https://en.chingcheng-law.com/news/details.php?id=66649

China Patent Strategy. (n.d.). Beijing Supreme People's Court upholds Novo Nordisk semaglutide patent in China based on post-filing data. *China Patent Strategy*. https://chinapatentstrategy.com/beijing-supreme-peoples-court-upholds-novo-nordisk-semaglutide-patent-in-china-based-on-post-filing-data/

Cornell Chronicle. (2025, December). Ozempic is changing the foods Americans buy. *Cornell Chronicle*. https://news.cornell.edu/stories/2025/12/ozempic-changing-foods-americans-buy

CZapp. (n.d.). Ozempic's patent protection starts to expire in 2026. What next? *CZapp*. https://www.czapp.com/analyst-insights/ozempics-patent-protection-starts-to-expire-in-2026-what-next/

Eagle IP. (n.d.). Beijing Supreme People's Court upholds Novo Nordisk semaglutide patent in China based on post-filing data. *Eagle IP*. https://eagle-ip.com/beijing-supreme-peoples-court-upholds-novo-nordisk-semaglutide-patent-in-china-based-on-post-filing-data/

The Economic Times. (n.d.). Zydus set for Day 1 launch of semaglutide generic with reusable multi-dose pen. *The Economic Times*. https://pharma.economictimes.indiatimes.com/news/pharma-industry/zydus-set-for-day-1-launch-of-semaglutide-generic-with-reusable-multi-dose-pen/128799190

Fintool. (n.d.). Novo Nordisk's CagriSema fails to match Eli Lilly's Zepbound in head-to-head REDEFINE 4 trial. *Fintool*. https://fintool.com/news/novo-cagrisema-redefine-4-fails-tirzepatide

Food Dive. (n.d.). Revisiting the predictions: How have GLP-1s changed the food industry? *Food Dive*. https://www.fooddive.com/news/opinion-glp-1-food-beverage-industry-predictions/814541/

GeneOnline. (n.d.). The 2026 GLP-1 patent cliff: Generics, global competition, and the $100 billion M&A race. *GeneOnline*. https://www.geneonline.com/the-2026-glp-1-patent-cliff-generics-global-competition-and-the-100-billion-ma-race/

WifiTalents. (2026). Ozempic food industry statistics: Data reports 2026. *WifiTalents*. https://wifitalents.com/ozempic-food-industry-statistics/

Whalesbook. (n.d.). India's semaglutide price war looms: 50+ generic brands spark race for patient care. *Whalesbook*. https://www.whalesbook.com/news/English/healthcarebiotech/Indias-Semaglutide-Price-War-Looms-50-Generic-Brands-Spark-Race-for-Patient-Care/69b024305b1fc118c08eb811

Whalesbook. (n.d.). Dr. Reddy's wins semaglutide export fight, sparks global generic race. *Whalesbook*. https://www.whalesbook.com/news/English/healthcarebiotech/Dr-Reddys-Wins-Semaglutide-Export-Fight-Sparks-Global-Generic-Race/69ae93286431e3e2859c92b3

Whalesbook. (n.d.). Dr. Reddy's joins generic semaglutide race: Price war looms. *Whalesbook*. https://www.whalesbook.com/news/English/healthcarebiotech/Dr-Reddys-Joins-Generic-Semaglutide-Race-Price-War-Looms/699eb35004a25a58c8540f8e

# BIBLIOGRAPHY


The Guardian. (2026, February 23). Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is labelled 'obsolete'. *The Guardian*. https://www.theguardian.com/business/2026/feb/23/wegovy-ozempic-weight-loss-drug-novo-nordisk-cagrisema

How low could semaglutide prices fall? An analysis of production cost and implications for global access ahead of patent expiry. (2026, March 4). *medRxiv* [Preprint]. https://www.medrxiv.org/content/10.64898/2026.03.04.26347508v1

How low could semaglutide prices fall? An analysis of production cost and implications for global access ahead of patent expiry. (n.d.). *ResearchGate*. https://www.researchgate.net/publication/401587887_How_Low_Could_Semaglutide_Prices_Fall_An_Analysis_of_Production_Cost_and_Implications_for_Global_Access_Ahead_of_Patent_Expiry

India Pharma Outlook. (n.d.). Semaglutide patent expiry sparks big generic drug opportunity. *India Pharma Outlook*. https://www.indiapharmaoutlook.com/news/semaglutide-patent-expiry-sparks-big-generic-drug-opportunity-nwid-4916.html

IQVIA. (2025, July). Off-patent semaglutide in 2026: The next revolution in anti-obesity medications. *IQVIA*. https://www.iqvia.com/locations/emea/blogs/2025/07/off-patent-semaglutide

KFF. (n.d.). Key facts about Medicare drug price negotiation. *KFF*. https://www.kff.org/medicare/key-facts-about-medicare-drug-price-negotiation/

Medpath. (n.d.). Novo Nordisk's CagriSema falls short against Eli Lilly's tirzepatide in obesity trial. *Medpath*. https://trial.medpath.com/news/fb6ed0ab2967164a/novo-nordisk-s-cagrisema-falls-short-against-eli-lilly-s-tirzepatide-in-obesity-trial

Medical Device Network. (n.d.). Dexcom reports 2025 revenues of $4.66bn yet 2026 outlook lags analyst expectations. *Medical Device Network*. https://www.medicaldevice-network.com/news/dexcom-reports-2025-revenue-of-4-bn-yet-2026-outlook-lags-analyst-expectations/

Medicare Rights Center. (2025, October 9). Negotiated prices take effect for ten drugs in 2026. *Medicare Rights Center*. https://www.medicarerights.org/medicare-watch/2025/10/09/negotiated-prices-take-effect-for-ten-drugs-in-2026

Medindia. (n.d.). How semaglutide's patent expiry could revolutionize obesity care in India. *Medindia*. https://www.medindia.net/news/healthinfocus/how-semaglutides-patent-expiry-could-revolutionize-obesity-care-in-india-222596-1.htm

Milliman. (n.d.). Medicare drug price negotiation: Navigating the next wave of maximum fair prices. *Milliman*. https://www.milliman.com/en/insight/medicare-drug-negotiation-next-maximum-fair-prices

Moneycontrol. (n.d.). Beyond the price war, Indian drug companies gearing up to win the GLP-1 retention game. *Moneycontrol*. https://www.tradingview.com/news/moneycontrol:8621c35f3094b:0-beyond-the-price-war-indian-drug-companies-gearing-up-to-win-the-glp-1-retention-game/

Morningstar. (n.d.). Novo Nordisk: Another disappointing CagriSema trial adds pressure to high-dose strategy. *Morningstar*. https://www.morningstar.com/stocks/novo-nordisk-another-disappointing-cagrisema-trial-adds-pressure-high-dose-strategy

The Motley Fool. (2026, February 25). Got $10,000? I think DexCom stock could be a quiet winner of the GLP-1 wars. *The Motley Fool*. https://www.fool.com/investing/2026/02/25/got-10000-i-think-dexcom-stock-could-be-a-quiet/

U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality. (2024). *FY2024 report on the state of pharmaceutical quality*. https://www.fda.gov/media/188153/download

The Times of India. (n.d.). Your weight-loss drugs set to become cheaper. *The Times of India*. https://timesofindia.indiatimes.com/business/india-business/your-weight-loss-drugs-set-to-become-cheaper/articleshow/128762477.cms

# BIBLIOGRAPHY


NACS. (2025, December 2). How Ozempic is shaping new shopping habits. *NACS*. https://www.convenience.org/Media/Daily/2025/December/2/4-How-Ozempic-Shaping-New-Shopping-Habits_Reseach

Nasdaq. (n.d.). Got $10,000? I think DexCom stock could be a quiet winner of the GLP-1 wars. *Nasdaq*. https://www.nasdaq.com/articles/got-10000-i-think-dexcom-stock-could-be-quiet-winner-glp-1-wars

Novo Nordisk A/S. (n.d.). CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved [Press release]. *BioSpace*. https://www.biospace.com/press-releases/novo-nordisk-a-s-cagrisema-demonstrated-23-weight-loss-in-an-open-label-head-to-head-redefine-4-trial-in-people-with-obesity-the-primary-endpoint-was-not-achieved

Pharma Business Hub. (n.d.). Semaglutide patent expiration date: What it means for prices and competition. *Pharma Business Hub*. https://pharmabusinesshub.com/semaglutide-patent-expiration-date/

Pharma Business Hub. (n.d.). Top semaglutide manufacturing companies dominating the global market. *Pharma Business Hub*. https://pharmabusinesshub.com/top-semaglutide-manufacturing-companies/

Pharmaceutical Technology. (n.d.). FDA issues warning to Novo Nordisk on unreported semaglutide safety events. *Pharmaceutical Technology*. https://www.pharmaceutical-technology.com/news/novo-nordisk-fda-warning-letter-semaglutide-adverse-event-reporting/

Reddie & Grose. (2026, February 9). Changes in the Ozempic patent landscape. *Reddie & Grose*. https://www.reddie.co.uk/2026/02/09/changes-in-the-ozempic-patent-landscape/

SNS Insider. (n.d.). Semaglutide patent expiry: ₹50,000 Cr pharma boost. *SNS Insider*. https://www.snsinsider.com/blogs/semaglutide-patent-expiry-a-windfall-for-indian-pharma

Telangana Today. (n.d.). Generic Ozempic versions to launch in India, prices to drop by 50 to 70%. *Telangana Today*. https://telanganatoday.com/generic-ozempic-versions-to-launch-in-india-prices-to-drop-by-50-to-70

The Times of India. (n.d.). When cost stops being the barrier: The new chapter of Ozempic injection in India. *The Times of India*. https://timesofindia.indiatimes.com/india/when-cost-stops-being-the-barrier-the-new-chapter-of-ozempic-injection-in-india/articleshow/129201298.cms




**IFSA RAMJAS**

Ramjas College, University Enclave

North Campus, Delhi-110007


IFSA

Ramjas